Pathogen inactivation in platelet concentrates: The French experience;Inactivation des pathogènes des concentrés plaquettaires: Expérience francaise

Transfusion Clinique et Biologique

Volumn 18, Issue 4, 2011, Pages 478-484

  Cazenave, J P ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Amotosalen; Blood plasma; Blood platelets; Blood transfusion; Clinical trials; Hemovigilance; Intercept ; Pathogen inactivation; Pathogens

Indexed keywords

AMOTOSALEN; THROMBOCYTE CONCENTRATE;

BACTERIAL TRANSMISSION; BACTERIUM DETECTION; BLOOD SAFETY; BLOOD STORAGE; CANCER CHEMOTHERAPY; DISEASE ASSOCIATION; ETHNICITY; HEMATOLOGY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; ONCOLOGY; PARASITE TRANSMISSION; PATHOGEN INACTIVATION TECHNOLOGY; PATHOGENICITY; PHOTOCHEMISTRY; PROCESS DESIGN; PROCESS TECHNOLOGY; RISK ASSESSMENT; SHORT SURVEY; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; VIRUS TRANSMISSION;

BLOOD-BORNE PATHOGENS; FRANCE; HUMANS; INFECTION CONTROL; PLATELET TRANSFUSION; PSORALENS; ULTRAVIOLET RAYS;

EID: 80051576132     PISSN: 12467820     EISSN: 19538022     Source Type: Journal    
DOI: 10.1016/j.tracli.2011.05.002     Document Type: Short Survey

References (23)

1. El Ghouzzi M.H., Rebibo D. Transfusion et risques résiduels. Rev Francophone Lab 2010, 426:79-83.
2. Stramer S.L., Hollinger E.B., Katz L.M., Kleinmann S., Metzel P.S., Gregory K.R., et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009, 49:1S-29S.
3. Zappa A., Amendola A., Romano L., Zanetti A. Emerging and re-emerging viruses in the era of globalisation. Blood Transfus 2009, 7:167-171.
4. Pozzetto B., Berthelot P. Virus émergents et ré-émergents et nouveaux risques nosocomiaux. Hygiene 2008, 16:1-11.
5. Walther-Wenke G., Wirsing von König C.H., Däubener W., Heiden M., Hoch J., Hornei B., et al. Monitoring bacterial contamination of blood components in Germany: effect of contamination reduction measures. Vox Sang 2011, 100:359-366.
6. Klein H.G., Anderson D., Bernardi M.J., Carey W., Hoch J.S., Robitaille N., et al. Pathogen inactivation: making decisions about new technologies-Preliminary report of a consensus conference. Vox Sang 2007, 93:179-182.
7. Webert K.E., Cserti C.M., Hannon J., Lin Y., Pavenski K., Pendergrast J.M., et al. Proceedings of a consensus conference: pathogen inactivation-Making decisions about new technologies. Transfus Med Rev 2008, 22:1-34.
8. Cazenave J.P. Inactivation des agents pathogènes dans les produits sanguins labiles: sécurité transfusionnelle et impact économique. Bull Acad Natl Med 2006, 190:169-188.
9. Naegelen C., Isola H., Dernis D., Maurel J.P., Tardivel R., Bois S., et al. Évolution des techniques de préparation des produits sanguins labiles (PSL): inactivation des pathogènes dans les PSL. Transfus Clin Biol 2009, 16:179-189.
10. Grass J.A., Hei D.J., Metchette K., Cimino G.D., Wiesehahn G.P., Corash L., et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998, 91:2180-2188.
11. Corash L., Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004, 33:1-7.
12. van Rhenen D., Gulliksson H., Cazenave J.P., Pamphilon D., Ljungman P., Kluter H., et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003, 101:2426-2433.
13. McCullough J., Vesole D.H., Benjamin R.J., Slichter S.J., Pineda A., Snyder E., et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004, 104:1534-1541.
14. Murphy S., Snyder E., Cable R., Slichter S.J., Strauss R.G., McCullough J., et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006, 46:4624-4633.
15. Lozano M., Knutson F., Tardivel R., Cid J., Maymo R.M., Lof H., et al. A multi-center study of therapeutic efficacy and safety of platelet components treated with amotosalen and UVA pathogen inactivation stored for 6 or 7 days prior to transfusion. Br J Haematol 2011, 153:393-401.
16. Cazenave J.P., Isola H., Waller C., Kientz D. France: intercept platelets and plasma. Pathogen inactivation: the penultimate paradigm shift 2010, 189-206. AABB Press, Bethesda, MD. J.P. AuBuchon, C.V. Prowse (Eds.).
17. Janetzko K., Cazenave J.P., Kluter H., Kientz D., Michel M., Beris P., et al. Therapeutic efficacy and safety of photochemically treated aphaeresis platelets processed with an optimized integrated set. Transfusion 2005, 45:1443-1452.
18. Rasongles P., Angelini-Tibert M.F., Simon P., Currie C., Isola H., Kientz D., et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de la Reunion. Transfusion 2009, 49:1083-1091.
19. Cazenave J.P., Isola H., Waller C., Mendel I., Kientz D., Laforet M., et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3 year period. Transfusion 2011, 51:622-629.
20. Osselaer J.C., Cazenave J.P., Lambermont M., Garraud O., Hidajat M., Barbolla L., et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008, 94:315-323.
21. Alter H.J. Pathogen reduction: a precautionary principle paradigm. Transfus Med Rev 2008, 22:97-102.
22. Cazenave J.P., Wiesel M.L., Mendel I., Faradji A., Mangin S., Perricard B., et al. Intensive and successful transfusion of pathogen inactivated Intercept® platelet concentrates for major gynecological and obstetrical surgery in Glanzmann thrombasthenia type 1 with the Gypsy mutation. Vox Sang 2008, 95:306.
23. Klein H.G., Glynn S.A., Ness P.M., Blajchman M.A. Research opportunities for pathogen reduction/inactivation of blood components: summary of an NHLBI workshop. Transfusion 2009, 49:1262-1268.